吉西他滨与长春瑞滨分别联合顺铂治疗晚期乳腺癌的疗效对比  

Efficacy Comparison of Gemcitabine Versus Vinorelbine Plus Cisplatin in the Treatment of Advanced Breast Cancer

作　　者：姚嘉[1] 李冠乔[1] 俞杨[1] 钟晓捷[1] 汤鹏[1] 

机构地区：[1]海南省人民医院乳腺外科,海南海口570311

出　　处：《医学临床研究》2015年第7期1299-1301,共3页Journal of Clinical Research

摘　　要：【目的】对比吉西他滨与长春瑞滨分别联合顺铂治疗晚期乳腺癌的临床疗效。【方法】选取对蒽环类和紫杉类药物耐药的晚期乳腺癌者70例，根据化疗方案不同分为吉西他滨（GEM）联合顺铂（DDP）（GP组）和长春瑞滨（NVB）联合DDP（NP组），每组35例。治疗2个周期后，比较两组患者的临床疗效及不良反应。【结果】GP组治疗有效率、疾病控制率分别为62．9％、82．9％，与NP组54．3％、77．1％比较差异无统计学意义（P〉0．05）。两种化疗方案均出现了不同程度的不良反应，其中GP组发生Ⅲ／Ⅳ度白细胞减少（25．7％）及血小板减少（34．3％）显著高于NP组（1I．4％，14．3％）（P〈0．05）；而静脉炎的发生率（28．6％）GP组显著低于NP组（45．7％）（P〈o．05）。【结论】GEM联合DDP与NVB联合DDP治疗蒽环类及紫杉类治疗失败的晚期乳腺癌的临床疗效相当，且均未见严重不良反应。[Objective] To compare the efficacy of gemcitabine versus vinorelbine plus cisplatin in the treatment of advanced breast cancer. [Methods] A total of 70 advanced breast patients not responding to anthracycline and/or taxane were selected from June 2013 to June 2014. According to different chemotherapeutic regimens, they were divided into gemcitabine （GEM） plus cisplatin （DDP） group （GP group） and vinorelbine （NVB） plus cisplatin （DDP） （NP group） （n=35 each）. After two cycles of treatment, clinical efficacy and adverse reactions were compared between two groups. [Results] The response and disease control rates were 62.9% and 82.9% in GP group versus 54.3% and 77.1% in NP group. No significant inter-group differences existed in response rate and disease control rate （ P 〉0.05）. There were different degrees of adverse reactions in two groups, The III/IV degree incidence of neutropenia （25.7%） and the incidence of phlebitis （34.3%） of GP group was significantly higher than those of NP group （11, 4 %, 14.3 % ）. The differences were statistically significant （ P 〈0.05）. And the incidence of thrombocytopenia was significantly lower in GP group than that in NP group （28.6% vs 45.7%, P 〈0, 05）. [Conclusion] Gemcitabine plus cisplatin and vinorelbine plus cisplatin are equally efficacious in the treatment of advanced breast cancer. There is no onset of serious adverse reactions.

关 键 词：脱氧胞苷/治疗应用 长春碱/治疗应用 顺铂/治疗应用 乳腺肿瘤/药物疗法 抗肿瘤联合化疗方案 

分 类 号：R737.9[医药卫生—肿瘤]